Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating)’s share price hit a new 52-week high on Friday . The stock traded as high as $31.01 and last traded at $30.90, with a volume of 41752 shares. The stock had previously closed at $29.19.
Wall Street Analyst Weigh In
RVNC has been the topic of several research analyst reports. Barclays increased their price target on shares of Revance Therapeutics from $35.00 to $37.00 and gave the company an “overweight” rating in a research note on Wednesday, November 16th. Morgan Stanley decreased their price target on shares of Revance Therapeutics from $27.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 9th. StockNews.com lowered shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 13th. Guggenheim increased their price objective on shares of Revance Therapeutics to $36.00 in a report on Tuesday, November 15th. Finally, Needham & Company LLC increased their price objective on shares of Revance Therapeutics from $35.00 to $38.00 and gave the company a “buy” rating in a report on Tuesday, January 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $38.20.
Revance Therapeutics Trading Up 8.6 %
The firm has a market cap of $2.61 billion, a P/E ratio of -8.09 and a beta of 0.57. The business’s 50-day moving average is $22.52 and its two-hundred day moving average is $22.06. The company has a debt-to-equity ratio of 2.60, a current ratio of 5.56 and a quick ratio of 5.33.
In other news, CFO Tobin Schilke sold 3,701 shares of Revance Therapeutics stock in a transaction dated Monday, January 9th. The shares were sold at an average price of $27.16, for a total value of $100,519.16. Following the completion of the transaction, the chief financial officer now owns 58,877 shares of the company’s stock, valued at approximately $1,599,099.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 5.10% of the company’s stock.
Institutional Trading of Revance Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the business. ProShare Advisors LLC raised its position in shares of Revance Therapeutics by 3.8% in the 3rd quarter. ProShare Advisors LLC now owns 14,057 shares of the biopharmaceutical company’s stock valued at $379,000 after buying an additional 516 shares in the last quarter. Amalgamated Bank grew its holdings in shares of Revance Therapeutics by 5.0% during the 3rd quarter. Amalgamated Bank now owns 11,607 shares of the biopharmaceutical company’s stock valued at $313,000 after purchasing an additional 555 shares during the last quarter. UBS Asset Management Americas Inc. grew its holdings in shares of Revance Therapeutics by 1.4% during the 3rd quarter. UBS Asset Management Americas Inc. now owns 69,815 shares of the biopharmaceutical company’s stock valued at $1,885,000 after purchasing an additional 983 shares during the last quarter. Guggenheim Capital LLC grew its holdings in shares of Revance Therapeutics by 2.9% during the 1st quarter. Guggenheim Capital LLC now owns 36,805 shares of the biopharmaceutical company’s stock valued at $718,000 after purchasing an additional 1,043 shares during the last quarter. Finally, Advisor Group Holdings Inc. grew its holdings in shares of Revance Therapeutics by 60.6% during the 1st quarter. Advisor Group Holdings Inc. now owns 2,838 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 1,071 shares during the last quarter. Institutional investors and hedge funds own 82.68% of the company’s stock.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.
- Get a free copy of the StockNews.com research report on Revance Therapeutics (RVNC)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.